Valley Retina Institute P.A.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Macular degeneration5 trials
• Diabetic eye disease3 trials

Phase

• Phase 24 trials
• Phase 33 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed4 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• AiViva BioPharma, Inc.1 trial
• EyePoint Pharmaceuticals, Inc.1 trial
• Genentech, Inc.1 trial
• ONL Therapeutics1 trial
• and 2 more

Running trials

• Recruiting

  Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

  NCT07557121· Phase 2· AiViva BioPharma, Inc.· Source

  Contact: Darlene C. Deecher, phd

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

  Contact: Study Coordinator

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

  NCT05608837· Phase 2· Quan Dong Nguyen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration3 recruiting

Closed trials

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

  NCT06771271· Phase 1· Hoffmann-La Roche· Source